Results 1 to 10 of about 96,968 (259)
Differences in Mpox and Vaccinia Immunity Induced by Non-Replicating and Replicating Vaccinia-Based Vaccines [PDF]
VaccinesBackground: The recent global outbreak with clade IIb and the concurrent emergence of clade I mpox virus in Africa show that mpox is a challenging problem. MVA-BN induces low-level mpox-neutralizing antibody responses that wane rapidly.
Getahun Abate +7 more
doaj +2 more sources
Optimizing Microneutralization and IFN-γ ELISPOT Assays to Evaluate Mpox Immunity [PDF]
VaccinesBackground: Available assays to measure pox virus neutralizing antibody titers are laborious and take up to 5 days. In addition, assays to measure T cell responses require the use of specific antigens, which may not be the same for all pox viruses.
Yinyi Yu +7 more
doaj +2 more sources
Emerging Infectious Diseases, 2010 When the World Health Organization declared smallpox eradicated in 1979, smallpox vaccination was discontinued worldwide. Although cessation of smallpox vaccination is well justified, given the risks associated with complications from the vaccine, lack of vaccination nevertheless creates a growing population of persons now susceptible to infection by a
Richard C. Condit
doaj +4 more sources
Frontiers in Immunology, 2021 Respiratory syncytial virus (RSV) is a leading cause of respiratory infections worldwide and disease management measures are hampered by the lack of a safe and effective vaccine against the infection.
Marsha S. Russell +18 more
doaj +1 more source
Possible Mpox Protection from Smallpox Vaccine–Generated Antibodies among Older Adults
Emerging Infectious Diseases, 2023 Smallpox vaccination may confer cross-protection to mpox. We evaluated vaccinia virus antibodies in 162 persons ≥50 years of age in Spain; 68.5% had detectable antibodies. Highest coverage (78%) was among persons 71–80 years of age.
Iván Sanz-Muñoz +9 more
doaj +1 more source